Managing Pain without Addiction
from The Bio Report Hosted by Levine Media Group
Opioid overdose, abuse, and addiction affect an estimated 3 million Americans and accounts for $35 billion in U.S. healthcare costs every year. Tris Pharma is developing the opioid Cebranopadol, as an effective pain management therapy without the addictive potential of FDA-approved opioids. We spoke to Ketan Mehta, founder and CEO of Tris Pharma, about Cebranopadol, how it modulates the addictive potential by targeting two receptors at once, and its potential to address the opioid crisis. An editor’s note: since recording this podcast, the National Institute on Drug Abuse, part of the National Institutes of Health, awarded Tris a five-year, $16.6 million grant to advance Cebranopadol.
Embed this episode
What this episode covers
Ketan Mehta, founder and CEO of Tris Pharma, discusses its experimental opiod Cebranopadol, how it modulates the addictive potential by targeting two receptors at once, and its potential to address the opioid crisis.
No transcript yet.